Action NTII NEUROBIOLOGICAL TECHNOLOGIES, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Neurobiological Technologies, Inc.

Actions

NTII

US64124W3043

Marché Fermé - OTC Markets
Autres places de cotation
 19:42:05 06/06/2024 		Varia. 5j. Varia. 1 janv.
0,0001 USD +9 900,00% Graphique intraday de Neurobiological Technologies, Inc. -.--% +9 900,00%

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
NEUROBIO TECH : Neurobiological Technologies Announces Extraordinary Dividend of $0.18 per Share
PR
NEUROBIO TECH : Neurobiological Technologies Announces Stockholder Approval of Plan of Liquidation and Dissolution
PR
NEUROBIO TECH : Neurobiological Technologies Announces Intent to File Form 25 to Delist Common Stock From the NASDAQ Capital Market
PR
NEUROBIO TECH : Neurobiological Technologies Receives Nasdaq Closing Bid Price Notification
PR
NEUROBIO TECH : Neurobiological Technologies Announces Termination of its License and Cooperation Agreement with Merz and Children's Medical Center
PR
NEUROBIOLO TCHNLGS : Neurobiological Technologies Reports Third Quarter Fiscal 2009 Financial Results
PR
NEUROBIOLO TCHNLGS : Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
PR
NEUROBIOLO TCHNLGS : Neurobiological Technologies Announces Hiring of Advisor to Seek Sale of Company
PR
NEUROBIOLO TCHNLGS : Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial Results
PR
NEUROBIOLO TCHNLGS : Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
PR
NEUROBIOLO TCHNLGS : Neurobiological Technologies Announces Suspension of Viprinex Development
PR
NEUROBIOLO TCHNLGS : Neurobiological Technologies Announces Viprinex(TM) Does Not Pass Interim Futility Analysis
PR
NEUROBIOLO TCHNLGS : Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results
PR
NEUROBIOLO TCHNLGS : Neurobiological Technologies to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York on November 10
PR
NEUROBIOLO TCHNLGS : Neurobiological Technologies Sets Date for First Quarter Financial Results
PR
NEUROBIOLO TCHNLGS : Neurobiological Technologies Reports Receipt of $2 Million Royalty Payment for Quarterly Sales of Memantine
PR
NEUROBIOLO TCHNLGS : Neurobiological Technologies to Present at the BIO Investor Forum in San Francisco on October 30, 2008
PR
NEUROBIOLO TCHNLGS : Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data
PR
NEUROBIOLO TCHNLGS : Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program
PR
NEUROBIOLO TCHNLGS : Analysis of Earlier European Stroke Trial Supports Treatment Regimen for Viprinex(TM) in Current International Phase 3 Clinical Trials
PR
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action NTII
  4. Actualités Neurobiological Technologies, Inc.
  5. Communiqués